GSK COX-2 Data Show No Short-Term Cardiovascular Risk, Company Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II agent has a safety profile similar to that of Celebrex but offers an “incremental” efficacy benefit over Pfizer’s drug, GSK says. NDA filing is tentatively scheduled for late 2006, but timing may depend on outcome of the Feb. 16-17 FDA advisory committee meeting on COX-2 safety issues.
You may also be interested in...
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
GSK Will Re-Do Phase II Wellbutrin Metabolite Studies At Higher Dose
GlaxoSmithKline will need to re-do its Phase II depression program for its metabolite of Wellbutrin (bupropion) after the 60 mg dose failed to meet the primary endpoint